3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
2
Completed
2
No longer available
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Interventions
Trastuzumab
379
Paclitaxel
369
Cyclophosphamide
338
Docetaxel
314
Capecitabine
198
Doxorubicin
196
Letrozole
183
Tamoxifen
154
Carboplatin
153
Fulvestrant
136
Bevacizumab
129
Anastrozole
120
exemestane
119
Lapatinib
117
Epirubicin
116
Gemcitabine
112
Radiotherapy
107
palbociclib
93
Exercise
87
Fluorouracil
83
Vinorelbine
82
Surveys and Questionnaires
81
pertuzumab
77
Albumin-Bound Paclitaxel
76
Filgrastim
71
130-nm albumin-bound paclitaxel
64
pembrolizumab
63
Everolimus
59
Cisplatin
59
eribulin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
glembatumumab vedotin
×
Breast
×
Clear all
NCT01997333
2019-03-08
METRIC
Celldex Therapeutics
Phase 2
Completed
327 enrolled
17 charts
NCT01156753
2017-07-02
EMERGE
Celldex Therapeutics
Phase 2
Completed
120 enrolled